Metabolic risk factors and skin cancer in the Metabolic Syndrome and Cancer Project (Me-Can)

British Journal of Dermatology

Volumn 167, Issue 1, 2012, Pages 59-67

  Nagel, Gabriele ^a,b   Bjorge T ^c,d   Stocks, T ^e,f   Manjer, J ^g   Hallmans, G ^g   Edlinger, M ^h   Haggstrom C ^e   Engeland, A ^b,d   Johansen, D ^g   Kleiner, A ^a   Selmer, R ⁱ   Ulmer, H ^g   Tretli, S ⁱ   Jonsson, H ^e   Concin, H ^b   Stattin, P ^e,j   Lukanova, A ^k  

^a UNIVERSITY OF ULM   (Germany)

^b AGENCY FOR PREVENTIVE AND SOCIAL MEDICINE   (Austria)

^c UNIVERSITY OF BERGEN   (Norway)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e UMEÅ UNIVERSITY   (Sweden)

^f The Capital Region   (Denmark)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁱ CANCER REGISTRY OF NORWAY   (Norway)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CANCER INCIDENCE; CANCER RISK; DISEASE ASSOCIATION; FATALITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METABOLIC SYNDROME X; NON MELANOMA SKIN CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TREND STUDY;

ADULT; AUSTRALIA; CASE-CONTROL STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MELANOMA; METABOLIC SYNDROME X; MIDDLE AGED; NORWAY; PROSPECTIVE STUDIES; RISK FACTORS; SKIN NEOPLASMS; SWEDEN;

EID: 84863318076     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10974.x     Document Type: Article

References (51)

1. Madan V, Lear JT, Szeimies R-M. Non-melanoma skin cancer. Lancet 2010; 375:673-85.
2. MacKie RM, Hauschild A, Eggermont AMM. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009; 20 (Suppl. 6):vi1-7.
3. Trakatelli M, Ulrich C, del Marmol V et al. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007; 156 (Suppl. 3):1-7. (Pubitemid 46646534)
4. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
5. Guy GP, Ekwueme DU. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature. Pharmacoeconomics 2011; 29:863-74.
6. Diffey BL, Langtry JAA. Skin cancer incidence and the ageing population. Br J Dermatol 2005; 153:679-80. (Pubitemid 41248242)
7. Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41:45-60. (Pubitemid 40029658)
8. Anderson WF, Pfeiffer RM, Tucker MA, Rosenberg PS. Divergent cancer pathways for early-onset and late-onset cutaneous malignant melanoma. Cancer 2009; 115:4176-85.
9. Shipman AR, Millington GWM. Obesity and the skin. Br J Dermatol 2011; 165:743-50.
10. Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569-78. (Pubitemid 351232031)
11. Thune I, Olsen A, Albrektsen G, Tretli S. Cutaneous malignant melanoma: association with height, weight and body-surface area. A prospective study in Norway. Int J Cancer 1993; 55:555-61. (Pubitemid 23328937)
12. Dennis LK, Lowe JB, Lynch CF, Alavanja MCR. Cutaneous melanoma and obesity in the Agricultural Health Study. Ann Epidemiol 2008; 18:214-21. (Pubitemid 351232237)
13. Stattin P, Björ O, Ferrari P et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007; 30:561-7. (Pubitemid 46354334)
14. Shu X, Ji J, Li X et al. Cancer risk among patients hospitalized for type 1 diabetes mellitus: a population-based cohort study in Sweden. Diabet Med 2010; 27:791-7.
15. Rosengren A, Himmelmann A, Wilhelmsen L et al. Hypertension and long-term cancer incidence and mortality among Swedish men. J Hypertens 1998; 16:933-40. (Pubitemid 28367947)
16. Stocks T, Borena W, Strohmaier S et al. Cohort profile: the Metabolic Syndrome and Cancer Project (Me-Can). Int J Epidemiol 2010; 39:660-7.
17. Bjørge T, Stocks T, Lukanova A et al. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 2010; 171:892-902.
18. Eurostat. European shortlist for causes of death. 2009. Available at: http://ec.europa.eu/health/major-chronic-diseases/mortality/causes-death/ index-en.htm (last accessed 26March 2011).
19. Clarke R, Shipley M, Lewington S et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999; 150:341-53. (Pubitemid 29383482)
20. Wood AM, White I, Thompson SG et al. Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. Int J Epidemiol 2006; 35:1570-8.
21. Fibrinogen Studies Collaboration. Correcting for multivariate measurement error by regression calibration in meta-analyses of epidemiological studies. Stat Med 2009; 28:1067-92.
22. Rapp K, Schroeder J, Klenk J et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 2006; 49:945-52.
23. Larsen IK, Småstuen M, Johannesen TB et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009; 45:1218-31.
24. Barlow L, Westergren K, Holmberg L, Talbäck M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009; 48:27-33.
25. Meyskens FL Jr, Farmer PJ, Anton-Culver H. Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk. Clin Cancer Res 2004; 10:2581-3. (Pubitemid 38509128)
26. Reichrath J. Skin cancer prevention and UV protection: how to avoid vitamin D-deficiency? Br J Dermatol 2009; 161 (Suppl. 3):54-60.
27. Lindgren AM, Nissinen AM, Tuomilehto JO, Pukkala E. Cancer pattern among hypertensive patients in North Karelia, Finland. J Hum Hypertens 2005; 19:373-9. (Pubitemid 40662858)
28. Edlinger M, Strohmaier S, Jonsson H et al. Blood pressure and other metabolic syndrome factors and risk of brain tumour in the large population-based Me-Can cohort study. J Hypertens 2012; 30:290-6.
29. Stocks T, van Hemelrijck M, Manjer J et al. Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension 2012; 59:802-10.
30. Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med 2002; 112:479-86. (Pubitemid 34450709)
31. Bedogni B, Powell MB. Hypoxia, melanocytes and melanoma - survival and tumor development in the permissive microenvironment of the skin. Pigment Cell Melanoma Res 2009; 22:166-74.
32. Mehnert JM, McCarthy MM, Jilaveanu L et al. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 2010; 41:375-84.
33. Beck B, Driessens G, Goossens S et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011; 478:399-403.
34. Facemire CS, Nixon AB, Griffiths R et al. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009; 54:652-8.
35. Freedman DM, Sigurdson A, Doody MM et al. Risk of melanoma in relation to smoking, alcohol intake, and other factors in a large occupational cohort. Cancer Causes Control 2003; 14:847-57. (Pubitemid 37500736)
36. Odenbro A, Gillgren P, Bellocco R et al. The risk for cutaneous malignant melanoma, melanoma in situ and intraocular malignant melanoma in relation to tobacco use and body mass index. Br J Dermatol 2007; 156:99-105. (Pubitemid 44929437)
37. Reeves GK, Pirie K, Beral V et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007; 335:1134.
38. de Giorgi V, Gori A, Grazzini M et al. Estrogens, estrogen receptors and melanoma. Expert Rev Anticancer Ther 2011; 11:739-47.
39. Gupta A, Driscoll MS. Do hormones influence melanoma? Facts and controversies. Clin Dermatol 2010; 28:287-92.
40. Brandon EL, Gu J-W, Cantwell L et al. Obesity promotes melanoma tumor growth: role of leptin. Cancer Biol Ther 2009; 8:1871-9.
41. Gogas H, Trakatelli M, Dessypris N et al. Melanoma risk in association with serum leptin levels and lifestyle parameters: a case-control study. Ann Oncol 2008; 19:384-9. (Pubitemid 351201725)
42. van Dam RM, Huang Z, Rimm EB et al. Risk factors for basal cell carcinoma of the skin in men: results from the health professionals follow-up study. Am J Epidemiol 1999; 150:459-68. (Pubitemid 29407229)
43. Olsen CM, Hughes MC, Pandeya N, Green AC. Anthropometric measures in relation to basal cell carcinoma: a longitudinal study. BMC Cancer 2006; 6:82.
44. Gerstenblith MR, Rajaraman P, Khaykin E et al. Basal cell carcinoma and anthropometric factors in the U.S. radiologic technologists cohort study. Int J Cancer 2011; [Epub ahead of print DOI: 10.1002/ijc.26480].
45. Antoniadis AG, Petridou ET, Antonopoulos CN et al. Insulin resistance in relation to melanoma risk. Melanoma Res 2011; 21:541-6.
46. Wotton CJ, Yeates DGR, Goldacre MJ. Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies. Diabetologia 2011; 54:527-34.
47. O'Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 1985; 38:435-41. (Pubitemid 15025864)
48. Ibiebele TI, van der Pols JC, Hughes MC et al. Dietary fat intake and risk of skin cancer: a prospective study in Australian adults. Int J Cancer 2009; 125:1678-84.
49. Ulmer H, Borena W, Rapp K et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer 2009; 101:1202-6.
50. Borena W, Stocks T, Jonsson H et al. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control 2011; 22:291-9.
51. Khovidhunkit W, Kim M-S, Memon RA et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004; 45:1169-96. (Pubitemid 38802622)